paricalcitol
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Secondary Hyperparathyroidism
Trial Timeline
Oct 1, 2011 → Apr 1, 2015
NCT ID
NCT01382212About paricalcitol
paricalcitol is a phase 3 stage product being developed by AbbVie for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01382212. Target conditions include End-Stage Renal Disease, Secondary Hyperparathyroidism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04064827 | Phase 3 | Terminated |
| NCT01382212 | Phase 3 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease